Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dela Cruz Chuh, Josefa, Go, MaryAnn, Chen, Yvonne, Guo, Jun, Rafidi, Hanine, Mandikian, Danielle, Sun, Yonglian, Lin, Zhonghua, Schneider, Kellen, Zhang, Pamela, Vij, Rajesh, Sharpnack, Danielle, Chan, Pamela, de la Cruz, Cecile, Sadowsky, Jack, Seshasayee, Dhaya, Koerber, James T., Pillow, Thomas H., Phillips, Gail D., Rowntree, Rebecca K, Boswell, C. Andrew, Kozak, Katherine R., Polson, Andrew G., Polakis, Paul, Yu, Shang-Fan, Dragovich, Peter S., Agard, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784788/
https://www.ncbi.nlm.nih.gov/pubmed/33382956
http://dx.doi.org/10.1080/19420862.2020.1862452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784788/
https://www.ncbi.nlm.nih.gov/pubmed/33382956
http://dx.doi.org/10.1080/19420862.2020.1862452

Ejemplares similares